Published in final edited form as:

Biochemistry. 2017 January 10; 56(1): 219–227. doi:10.1021/acs.biochem.6b00976.

Prolyl 4-Hydroxylase: Substrate Isosteres in Which an (*E*)- or (*Z*)-Alkene Replaces the Prolyl Peptide Bond

James D. Vasta^{†,‡}, Amit Choudhary^{§,¶}, Katrina H. Jensen^{⊥,||}, Nicholas A. McGrath^{⊥,▽}, and Ronald T. Raines^{†,⊥,*}

[†]Department of Biochemistry, University of Wisconsin-Madison, Madison, Wisconsin 53706, United States

[§]Graduate Program in Biophysics, University of Wisconsin-Madison, Madison, Wisconsin 53706, United States

[⊥]Department of Chemistry, University of Wisconsin-Madison, Madison, Wisconsin 53706, United States

Abstract

Collagen prolyl 4-hydroxylases (CP4Hs) catalyze a prevalent posttranslational modification—the hydroxylation of (2*S*)-proline residues in procollagen strands. The ensuing (2*S*,4*R*)-4-hydroxyproline residues are necessary for the conformational stability of the collagen triple helix. Prolyl peptide bonds isomerize between *cis* and *trans* isomers, and the preference of the enzyme is unknown. We synthesized alkene isosteres of the *cis* and *trans* isomers to probe the conformational preferences of human CP4H1. We discovered that the presence of a prolyl peptide bond is necessary for catalysis. The *cis* isostere is, however, an inhibitor with potency greater than that of the *trans* isostere, suggesting that the *cis* conformation of a prolyl peptide bond is recognized preferentially. Comparative studies with a *Chlamydomonas reinhardtii* P4H, which has a similar catalytic domain but lacks an N-terminal substrate-binding domain, showed a similar preference for the *cis* isostere. These findings support the hypothesis that the catalytic domain of CP4Hs recognizes the *cis* conformation of the prolyl peptide bond and inform the use of alkenes as isosteres for peptide bonds.

Graphical Abstract

*Corresponding Author, rtraines@wisc.edu.

‡Present Addresses

Promega Corporation, 2800 Woods Hollow Road, Fitchburg, Wisconsin 53711, United States

¶Department of Medicine, Harvard Medical School, Boston, Massachusetts 02115, United States

||Chemistry Program, Black Hills State University, Spearfish, South Dakota 57799, United States

▽Department of Chemistry and Biochemistry, University of Wisconsin-La Crosse, La Crosse, Wisconsin 54601, United States

ASSOCIATED CONTENT

Supporting Information

The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/acs/bio-chem.xxxxxxx.

Procedures for the synthesis of compounds 1–6 (PDF)

The authors declare no competing financial interest.

Collagen is the principal component of the extracellular matrix, connective tissues, and bone of animals.¹ The overproduction of collagen is associated with a variety of diseases, including fibrotic diseases² and cancers.^{3–7} The stability of collagen relies on posttranslational modifications.⁸ By far the most common of these modifications is mediated by collagen prolyl 4-hydroxylases (CP4Hs), which are Fe(II)- and α-ketoglutarate-dependent dioxygenases (FAKGDs) that reside in the lumen of the endoplasmic reticulum.⁹ Catalysis by CP4Hs converts (2*S*)-proline (Pro) residues in procollagen strands into (2*S*, 4*R*)-4-hydroxyproline (Hyp) residues (Figure 1A), which endow mature collagen triple helices with conformational stability.¹⁰ CP4Hs, while essential for animal life,^{11–13} are validated targets for treating fibrotic diseases¹⁴ and metastatic breast cancer.⁶

Catalysis by CP4Hs and other FAKGDs requires Fe(II) and the cosubstrates α-ketoglutarate and molecular oxygen.^{15–17} The Fe(II) is bound by a conserved His-X-Asp/Glu...X_n...His motif, and α-ketoglutarate chelates to the enzyme-bound Fe(II) by using its C-1 carboxylate and C-2 keto groups while its C-5 carboxylate group forms hydrogen bonds and engages in Coulombic interactions with a basic residue (often arginine or lysine; Figure 1B). All FAKGDs are believed to effect catalysis through a two-stage mechanism in which α-ketoglutarate is decarboxylated oxidatively to generate a highly reactive Fe(IV)=O species that elicits substrate oxidation via a radical rebound process.^{15–18}

In vertebrates, CP4Hs exist as α₂β₂ tetramers. In these tetramers, the α-subunit contains the C-terminal catalytic domain and N-terminal peptide-substrate-binding domain (PSB domain). The β-subunit is protein disulfide isomerase, which is a multifunctional protein that maintains the α-subunit in a soluble form and active conformation.⁹ Humans have three isoforms of the α-subunit: α(I), α(II), and α(III).⁹ All three of these isoforms interact with a single β-subunit to form tetramers, which are known as CP4H1, CP4H2, and CP4H3, respectively. CP4H1 is the most prevalent of these holoenzymes, and has been characterized most extensively. Although the structure of the tetrameric complex is unknown, those of the individual domains of the α(I)-subunit have provided insight into the interaction of CP4Hs with the procollagen substrate, as well as the interaction of two α(I)-subunits in the tetramer.^{19–22}

Many features of the reaction catalyzed by CP4Hs are well known.⁹ Moreover, the development of CP4H inhibitors is of keen interest.^{2,14,23,24} Like others,²⁵ we have directed our attention toward inhibitors that mimic the α-ketoglutarate co-substrate.^{12,26–28} Because many enzymes use α-ketoglutarate as a substrate or co-substrate, CP4H inhibitors based upon the procollagen substrate could offer improved selectivity. CP4H is recalcitrant to substitutions in its Fe(II)-binding motif.²⁹ The enzyme can, however, tolerate alterations in

its substrate.^{30–33} For example, CP4H catalyzes the hydroxylation of proline analogs that bear a substitution at C β , C γ , or C δ (Figure 1C).

Little is known about the conformation of the peptide substrate during catalysis. Proline is a secondary amine and prolyl peptide bonds are tertiary amides. Accordingly, the *cis* isomer of prolyl peptide bonds (Figure 2A) occurs much more frequently than with non-prolyl residues.³⁴ Biochemical and biophysical investigations have suggested that β -turns are sites of prolyl hydroxylation.^{35–37} β -Turns can have *cis* or *trans* prolyl peptide bonds,³⁸ and the isomerization state of the peptide bond in CP4H substrates is unknown, as is the necessity of even having a peptide bond. Here, we probe this fundamental issue by using alkene isosteres, which delete the peptide bond while preserving its geometric constraints. We describe the synthesis of collagen mimetic peptides in which a prolyl peptide bond is replaced with a (*E*)- or (*Z*)-alkene, which are the smallest isosteres that fix the bond as a *trans* or *cis* isomer, respectively.³⁹ We find that the presence of a peptide bond is necessary for catalysis by both human CP4H1 and a related P4H from the algae *Chlamydomonas reinhardtii* (CrP4H1⁴⁰). These enzymes prefer to bind to the *cis* isostere relative to the *trans*, and recognition of the *cis* isostere likely occurs in the catalytic domain. These results provide new insight into catalysis by prolyl 4-hydroxylases.

EXPERIMENTAL PROCEDURES

Peptide synthesis

Detailed procedures for the synthesis of peptides **1** and **2**, *trans* isosteres **3** and **4** (Scheme 1), and *cis* isosteres **5** and **6** (Scheme 2) are reported in the Supporting Information.

Instrumentation

The progress of reactions catalyzed by prolyl 4-hydroxylases was assessed by analytical UPLC using an Acquity UPLC[®] H-Class system from Waters (equipped with a photodiode array detector, quaternary solvent manager, sample manager with a flow-through needle, and Empower 3 software). The concentration of dansyl-labeled peptides was determined with a Cary 60 UV–Vis Spectrometer from Agilent Technologies (Santa Clara, CA) using an extinction coefficient of 3,900 M^{–1}cm^{–1}. Solution concentrations of proteins were calculated with the Beer–Lambert law from $A_{280\text{ nm}}$ values as measured with a NanoVue Plus spectrophotometer from GE Healthcare (Piscataway, NJ) and extinction coefficients of 290,000 M^{–1}cm^{–1} for human CP4H1⁴¹ and 44,000 M^{–1}cm^{–1} for CrP4H-1 (which was estimated with EXPASY software by assuming that all cysteine residues form disulfide bonds). Values of IC₅₀ were calculated from experimental data with the program Prism version 6.0 from GraphPad Software (La Jolla, CA).

Production of Recombinant Human CP4H1

Human CP4H containing the α (I) isoform was produced heterologously in Origami B(DE3) *Escherichia coli* cells and purified as described previously.⁴¹

Stock Solutions for Assays

Assay mixtures were made from the following stock solutions. A stock solution of Tris–HCl buffer (10×) was prepared at 500 mM, pH 7.8, in H₂O. A stock solution of α-ketoglutarate (10×) was prepared in H₂O. A stock solution of FeSO₄ (10×) was prepared at 500 μM in H₂O. A stock solution of sodium ascorbate (10×) was prepared at 20 mM in H₂O. A stock solution of DTT (10×) was prepared freshly on the day of its use at 1.0 mM in H₂O. A stock solution of catalase (10×) was prepared freshly on the day of its use at 1.0 mg/mL in 50 mM Tris–HCl buffer, pH 7.8. A stock solution of BSA (10 mg/mL) was prepared in 50 mM Tris–HCl buffer, pH 7.8. Concentrated stock solutions of the dansylGPPGOEt substrate and alkene isosteres were prepared in EtOH and diluted to working stock solutions (10×) in H₂O.

Assay of Human CP4H1 Activity in the Presence of Alkene Isosteres

The catalytic activity of human CP4H1 was assayed as described previously.⁴¹ Briefly, activity assays were performed at 30 °C in 100 μL of 50 mM Tris–HCl buffer, pH 7.8, containing human CP4H1 (100 nM), substrate (0–1.86 mM), alkene isostere (0–3.00 mM), α-ketoglutarate (13–1000 μM), FeSO₄ (50 μM), sodium ascorbate (2 mM), DTT (100 μM), catalase (0.1 mg/mL to decompose any hydrogen peroxide), and BSA (1 mg/mL). Unless noted otherwise, reaction mixtures were prepared by adding concentrated stock solutions of each component to concentrated assay buffer in this order: FeSO₄, DTT, sodium ascorbate, BSA, catalase, CP4H1, peptide substrate, and alkene isostere (or vehicle). Solutions prepared thusly were pre-incubated at 30 °C for 2 min, after which a reaction was initiated by the addition of α-ketoglutarate. After 15 min, reactions were quenched by boiling for 45 s, and reaction mixtures were subjected to centrifugation at 10,000g. The supernatant (5–10 μL) was injected into an Acquity UPLC[®] BEH C18 column (2.1 × 50 mm, 1.7-μm particle size) from Waters. The column was eluted for 2.9 min at 0.6 mL/min with a linear gradient of acetonitrile (20–68% v/v) in water containing TFA (0.1% v/v) while monitoring the value of *A*_{289 nm}. All assays were performed in triplicate. Data are reported as activity relative to control reactions lacking an alkene isostere, where activity is determined from the percent conversion of substrate to product. Dose–response curves were generated for each isostere by plotting the relative activity versus the log of isostere concentration. Values of IC₅₀ for each isostere were interpolated from the dose–response curves by non-linear regression using the sigmoidal dose–response function available in Prism. For substrate inhibition by dansylGlyProProGlyOEt, data were fitted to the substrate-inhibition function in Prism.

Production of Recombinant *C. reinhardtii* P4H-1

C. reinhardtii P4H-1_{30–245} having an N-terminal hexahistidine (His₆) tag (NHis₆-CrP4H-1) was produced heterologously in Origami B(DE3) *Escherichia coli* cells and purified as described previously.⁴²

Assay of *C. reinhardtii* P4H-1 Activity in the Presence of Alkene Isosteres

The catalytic activity of NHis₆-CrP4H-1 was assessed in assays similar to those for human CP4H1 with minor modification. Briefly, activity assays were carried out at 30 °C in 100 μL of 50 mM HEPES–HCl buffer, pH 6.8, containing NHis₆-CrP4H-1 (1.2 μM), substrate

dansylGlyProProGlyOEt (500 μ M), alkene isostere (0–100 μ M), α -ketoglutarate (1 mM), FeSO₄ (200 μ M), sodium ascorbate (2 mM), DTT (100 μ M), catalase (0.1 mg/mL), and BSA (1 mg/mL). Reaction mixtures were prepared by adding concentrated stock solutions of each component to concentrated assay buffer in this order: FeSO₄, DTT, sodium ascorbate, BSA, catalase, NHis₆-CrP4H-1, peptide substrate, and alkene isostere (or vehicle). Solutions prepared thusly were pre-incubated at 30 °C for 2 min, after which a reaction was initiated by the addition of α -ketoglutarate. After 1 h, reactions were quenched by adding EDTA (1 μ L of a 0.5 M solution) and boiling for 45 s. Quenched reaction mixtures were subjected to centrifugation at 10,000*g* for 5 min, after which the supernatant (5–10 μ L) was analyzed by UPLC as described above.

RESULTS AND DISCUSSION

Synthesis of Alkene Isosteres

The primary substrates for CP4Hs *in vivo* are procollagens and other large polymers (*i.e.*, elastin).⁹ These large protein substrates are not amenable to most chemical analyses. Hence, we chose to employ a model system based upon a small collagen mimetic tetrapeptide: GlyProProGlyOEt (GPPGOEt), with corresponding alkene isosteres GP*trans*PGOEt and GP*cis*PGOEt (Figure 2). Small tetrapeptides of this nature that contain one collagen-like triplet repeat have been found previously to be suitable substrates for CP4Hs.^{27,32,33,37,41} We chose to use model peptides capped with an N-terminal dansyl sulfonamide, which are well-known to be substrates for human CP4H,^{27,41} as well as peptides capped with an N-terminal Cbz group^{30,31} for supplemental analyses (Figure 2). The model substrates dansylGPPGOEt (**1**) and CbzGPPGOEt (**2**) were synthesized by standard solution-phase peptide coupling procedures as described previously for similar peptides.²⁷

Trans isosteres dansylGP*trans*PGOEt (**3**) and CbzGP*trans*PGOEt (**4**) were synthesized from Boc-Pro-OH in 11 steps by a route (Scheme 1) adapted from previous reports by Etzkorn, Koert, and coworkers.^{43–47} The facial selectivity in the conversion of aldehyde **9** to alcohol **10** is particularly striking. The Boc group in aldehyde **9** blocks the *si* face of the aldehyde, leading to (*S*)-configured alcohol **10**. (The stereochemistry of alcohol **10** was confirmed by X-ray crystallography.) The key step in the route relied on the stereoselective Ireland–Claisen rearrangement of allyl ester **12** to γ,δ -alkenyl acid **13** in nearly quantitative yield.⁴⁸ Standard transformations led to acid **17**, which was then coupled with H-Gly-OEt by using a hindered base, 2,4,6-collidine, to avoid isomerization of the olefin. Lastly, deprotection of the N-terminal Boc group of alkene **18** followed by coupling with dansyl-Gly-OH or Cbz-Gly-OH yielded *trans* isosteres **3** or **4**, respectively. These isosteres had characteristic alkene ¹H chemical shifts at 5–6 ppm, indicating that the alkene did not isomerize to be in conjugation with the amidic carbonyl group.

The corresponding *cis* isosteres dansylGP*cis*PGOEt (**5**) and CbzGP*cis*PGOEt (**6**) were synthesized from Bn-Pro-OH in 9 steps by a route (Scheme 2) inspired by the work of Etzkorn and coworkers.^{43,49} A variety of reducing agents were evaluated for the stereoselective reduction of ketone **21**, including L-Selectride, K-Selectride, NaBH₄, DIBALH, and LiAlH₄. The highest yields of alcohol **22** were afforded by LiAlH₄, but as a

nearly equimolar mixture of diastereomers. Although the desired diastereomer of alcohol **22** was isolable, the separation of diastereomers following alkylation to ether **23** was more facile. (The stereochemistry of the two diastereomers of alcohol **22** was assigned by forming the two oxazolidinones and using ^1H NMR spectroscopy.) The key step in the route employed a stereoselective Still–Wittig rearrangement⁵⁰ of ether **23** to afford alkene **24** in 86% yield. As with the synthesis of the *trans* isosteres, the coupling of H-Gly-OEt to acid **26** worked well when mediated by 2,4,6-collidine. Lastly, deprotection of the N-terminal Boc group of alkene **27** followed by subsequent coupling of dansyl-Gly-OH or Cbz-Gly-OH yielded *cis* isosteres **5** or **6**, respectively. Again, these isosteres had characteristic alkene ^1H chemical shifts at 5–6 ppm, indicating that the alkene did not isomerize to be in conjugation with the amidic carbonyl group. Analytical UPLC revealed that compounds **1–6** were of high purity.

Interaction of Model Peptides and Alkene Isosteres with Human CP4H

With the model peptides and corresponding alkene isosteres in hand, we set out to probe their interaction with human CP4H. First, we tested the model peptides (**1** and **2**) as substrates for human CP4H by employing a UPLC assay that was adapted from an HPLC assay described previously.^{27,32,41} Initial tests confirmed that both dansylGPPGOEt and CbzGPPGOEt were substrates for human CP4H1, as expected from previous reports.^{27,41} In contrast, neither the *cis* nor the *trans* isosteres (**3–6**) served as substrates for the enzyme (data not shown), regardless of concentration (0.1–3.0 mM for dansyl isosteres; 0.1–10 mM for Cbz isosteres).

Although isosteres **3–6** did not serve as substrates for human CP4H, we reasoned that they might serve as inhibitors. Using the dansyl model peptides, we found that both dansylGP*trans*PGOEt and dansylGP*cis*PGOEt were indeed inhibitors of catalysis by human CP4H (Figure 3A), with the *cis* isostere being significantly more potent than the *trans*. In subsequent dose–response experiments, the inhibition curves for both dansyl isosteres were found to be sigmoidal (Figure 3B), with IC_{50} values of $(75 \pm 6) \mu\text{M}$ and $(410 \pm 30) \mu\text{M}$ for the *cis* and *trans* isosteres, respectively. Moreover, this same trend in which the *cis* isostere inhibits with greater potency than does the *trans* isostere was also observed with the Cbz-capped isosteres **4** and **6** (Figure 3C), indicating that the trend is independent of the N-terminal group. These data are consistent with a previous correlation indicating that substrates for human CP4H1 tend to have greater preference for a *cis* prolyl peptide bond.³² In contrast to isosteres **3–6**, however, none of those previous substrates were fixed as a *cis* (or *trans*) isomer. Due to more reliable quantitation and sensitivity compared to the Cbz-peptides, we proceeded with the dansyl isosteres **3** and **5** in subsequent analyses.

With an interest in characterizing further the inhibition observed for the dansyl isosteres, we next considered their kinetic mechanism. CP4Hs have been shown previously to display an ordered *ter–ter* mechanism in which α -ketoglutarate first binds to the CP4H·Fe(II) complex, after which O_2 and the peptide substrate bind in an ordered fashion.⁵¹ We found that turnover of dansylGPPGOEt did not display Michaelis–Menten kinetics, but rather a pattern recognizable as substrate inhibition (Figure 4A), which was evident in the corresponding

Lineweaver–Burke plot (Figure 4B). The data in Figure 4A were fitted to the equation for substrate inhibition:

$$v = \frac{V_{\max}[S]}{K_M + [S] + \frac{[S]^2}{K_i}}$$

where K_i is the dissociation constant for substrate binding in an inhibitory manner. This fit ($R^2 = 0.98$) yielded values for $V_{\max}$, K_M , and K_i of $(8 \pm 3) \mu\text{M}\cdot\text{min}^{-1}$, $(2.0 \pm 0.8) \text{ mM}$, and $(0.3 \pm 0.1) \mu\text{M}$, respectively.

Substrate inhibition had been observed previously for a CP4H during turnover of a longer collagen mimetic peptide substrate, (ProProGly)₁₀.⁵¹ Moreover, that substrate inhibition was competitive with the cosubstrate α -ketoglutarate. Substrate inhibition by dansylGPPGOEt in our assays was, however, observed even at saturating concentrations of α -ketoglutarate, suggesting that the inhibitory binding mode of dansylGPPGOEt could not be eliminated in this manner.

Given the complexities in the kinetics with respect to the peptide substrate, we reasoned that, if the kinetic mechanism entailed ordered binding, then the dansyl isosteres would display uncompetitive inhibition versus the α -ketoglutarate cosubstrate. We performed a Lineweaver–Burke analysis using *cis* isostere **5** as a model inhibitor, but found an inhibition pattern consistent with noncompetitive inhibition versus α -ketoglutarate (Figure 5A). The slope (Figure 5B) and intercept (Figure 5C) replots for the noncompetitive inhibition were linear, and K_{is} and K_{ii} values of $(56 \pm 13) \mu\text{M}$ and $(18 \pm 8) \mu\text{M}$, respectively, were extracted from the slope (K_{is}) and intercept (K_{ii}) replots by linear regression analysis. This value for K_{is} is indistinguishable from the IC_{50} value of $(76 \pm 13) \mu\text{M}$ for *cis* isostere **5**. The observation of noncompetitive inhibition for *cis* isostere **5** versus α -ketoglutarate suggests either that this isostere binds in a CP4H subsite that is independent of the site for hydroxylation, or that the binding of the small collagenous tetrapeptides is not strictly ordered relative to the co-substrates α -ketoglutarate and molecular oxygen. Kinetic experiments cannot distinguish between these two possibilities.

Preliminarily, the inhibition pattern reported above is consistent with the hypothesis that human CP4H preferentially binds to the *cis* conformation compared to the *trans* conformation in collagen-like peptides. The CP4H α -subunit is composed of multiple domains, including a C-terminal catalytic domain and N-terminal PSB domain,^{9,14} both of which likely interact with a typical polymeric substrate. The structure of the PSB domain has been characterized, and is known to interact with peptides in a PPII helical conformation, which has *trans* peptide bonds.^{20–22} Accordingly, we were not surprised to learn that human CP4H has some affinity for *trans* isostere **3**, which is likely to adopt an extended conformation similar to that of a PPII helix. Given its locked conformation, however, *cis* isostere **5** is less likely to interact favorably with the PSB domain, which raises the issue of whether or not the C-terminal catalytic domain is responsible for preferential recognition of the *cis* conformation.

To address this issue, we sought a more simple P4H model system. We chose to investigate CrP4H-1, which is an algal P4H.⁴⁰ CrP4H-1 is a soluble, 29-kDa monomer with 26% identity in amino-acid sequence to the catalytic domain of human CP4H⁴⁰ and a known three-dimensional structure.^{52,53} FAKGD enzymes are generally conserved at the level of fold,¹⁶ and all essential active-site residues are conserved in the two P4Hs.⁴⁰ Moreover, although substrates for algal P4Hs such as CrP4H-1 are typically proline- and serine-rich polymers of the algal cell wall *in vivo*, CrP4H-1 has been observed to turn over collagen-like peptides, albeit with less positional specificity (*e.g.*, CrP4H-1 catalyzes the hydroxylation of proline residues in both the X- and the Y-position).⁴⁰

As CrP4H-1 can be viewed as a reasonable model system for the catalytic domain of the human CP4H1 α -subunit, we sought to investigate the interaction of dansyl peptides **1**, **3**, and **5** with CrP4H-1. Under an assay condition similar to that used to assay human CP4H1, we found that model peptide **1** served as a substrate for CrP4H-1, albeit with a substrate inhibition phenomenon similar to that observed for human CP4H1 (Figure 6). Again, we did not observe hydroxylation of the dansyl isosteres **3** or **5** by CrP4H-1 (data not shown). We did find, however, that both dansyl isosteres **3** and **5** served as inhibitors of CrP4H-1. We observed an inhibition pattern virtually identical to that observed for human CP4H1, again with *cis* isostere **5** displaying significantly greater potency than that of *trans* isostere **3** (Figure 7). Similar to human CP4H1, these data suggest that CrP4H-1 preferentially recognizes the *cis* conformation in peptide substrate analogs. Given the similarities between human CP4H1 and the algal CrP4H-1, as well as CrP4H-1 being (in essence) a monomeric catalytic domain, our data suggest that the catalytic domains of both P4Hs preferentially recognize the *cis* conformation of prolyl peptide bonds.

Product inhibition is often detrimental to enzyme function.^{54–56} This problem could be especially acute with CP4H because of the abundance of collagen strands in the endoplasmic reticulum. The installation of a 4(*R*)-hydroxyl group is known to decrease the fraction of prolyl peptide bonds that reside in the *cis* conformation.^{57,58} Taken with our data, this increase in *trans:cis* ratio could lessen product inhibition. We note as well that the hydrophilicity conferred by hydroxylation could diminish affinity for hydrophobic pockets of the PSB domain.²²

Neither the *cis* nor the *trans* prolyl peptide bond isostere serve as a substrate for CP4H. This result suggests that CP4H interrogates substitutions at the prolyl peptide bond of its substrate more closely than those near C γ (Figure 1C). Numerous explanations are possible for this intolerance. The substitution could eliminate a key hydrogen bond between the enzyme and the amidic oxygen (O $_{i-1}$) of the prolyl peptide bond, perturbing the orientation of the substrate. The substitution could affect the substrate conformation by preventing two potential $n \rightarrow \pi^*$ interactions,^{46,59–61} one with the C' $_{i-1}$ =O $_{i-1}$ as a donor and one with C' $_{i-1}$ =O $_{i-1}$ as an acceptor. Finally, conformational mobility of the prolyl peptide bond (even its *cis-trans* isomerization) could play an integral role in catalysis by CP4H. These scenarios are the basis for on-going work in our laboratory.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We are grateful to Drs. B. Gold, M. D. Shoulders, K. L. Gorres, I. A. Guzei, and C. L. Jenkins (University of Wisconsin–Madison) for contributive discussions.

Funding

J.D.V. was supported by Molecular Biosciences Training Grant T32 GM007215 (NIH) and a fellowship from the Department of Biochemistry at the University of Wisconsin–Madison. K.H.J. was supported by postdoctoral fellowship F32 GM098032 (NIH). N.A.M. was supported by postdoctoral fellowship F32 GM096712 (NIH). This work was supported by Grant R01 AR044276 (NIH), and made use of the National Magnetic Resonance Facility at Madison, which is supported by Grant P41 GM103399 (NIH), and a Micromass LCT[®] mass spectrometer, which was obtained with support from Grant CHE-9974839 (NSF).

REFERENCES

1. Shoulders MD, Raines RT. Collagen structure and stability. *Annu. Rev. Biochem.* 2009; 78:929–958. [PubMed: 19344236]
2. Rosenbloom J, Castro SV, Jimenez SA. Narrative review: Fibrotic diseases: Cellular and molecular mechanisms and novel therapies. *Ann. Intern. Med.* 2010; 152:159–166. [PubMed: 20124232]
3. Provenzano PP, Inman DR, Eliceiri KW, Knittel JG, Yan L, Rueden CT, White JG, Keely PJ. Collagen density promotes mammary tumor initiation and progression. *BMC Med.* 2008; 6:11. [PubMed: 18442412]
4. Conklin MW, Eickhoff JC, Riching KM, Pehlke CA, Eliceiri KW, Provenzano PP, Friedi A, Keely PJ. Aligned collagen is a prognostic signature for survival in human breast carcinoma. *Am. J. Pathol.* 2011; 178:1221–1232. [PubMed: 21356373]
5. Eisinger-Mathason TS, Zhang M, Qiu Q, Skuli N, Nakazawa MS, Karakasheva T, Mucaj V, Shay JES, Stangenberg L, Sadri N, Puré E, Yoon SS, Kirsch DG, Simon MC. Hypoxia-dependent modification of collagen networks promotes sarcoma metastasis. *Cancer Discov.* 2013; 3:1190–1205. [PubMed: 23906982]
6. Gilkes DM, Chaturvedi P, Bajpai S, Wong CC, Wei H, Pitcairn S, Hubbi ME, Wirtz D, Semenza GL. Collagen prolyl hydroxylases are essential for breast cancer metastasis. *Cancer Res.* 2013; 73:3285–3296. [PubMed: 23539444]
7. Cox TR, Bird D, Baker A-M, Barker HE, Ho MW-Y, Lang G, Erler JT. Lox-mediated collagen crosslinking is responsible for fibrosis-enhanced metastasis. *Cancer Res.* 2014; 73:1721–1732.
8. Myllyharju J, Kivirikko KI. Collagens, modifying enzymes and their mutations in humans, flies and worms. *Trends Genet.* 2004; 20:33–43. [PubMed: 14698617]
9. Gorres KL, Raines RT. Prolyl-4-hydroxylase. *Crit. Rev. Biochem. Mol. Biol.* 2010; 45:106–124. [PubMed: 20199358]
10. Berg RA, Prockop DJ. The thermal transition of a non-hydroxylated form of collagen. Evidence for a role for hydroxyproline in stabilizing the triple helix of collagen. *Biochem. Biophys. Res. Comm.* 1973; 52:115–120. [PubMed: 4712181]
11. Winter AD, Page AP. Prolyl 4-hydroxylase is an essential procollagen-modifying enzyme required for exoskeleton formation and the maintenance of body shape in the nematode *Caenorhabditis elegans*. *Mol. Cell Biol.* 2000; 20:4084–4093. [PubMed: 10805750]
12. Friedman L, Higgin JJ, Moulder G, Barstead R, Raines RT, Kimble J. Prolyl 4-hydroxylase is required for viability and morphogenesis in *Caenorhabditis elegans*. *Proc. Natl. Acad. Sci. USA.* 2000; 97:4736–4741. [PubMed: 10781079]
13. Holster T, Pakkanen O, Soininen R, Sormunen R, Nokelainen M, Kivirikko KI, Myllyharju J. Loss of assembly of the main basement membrane collagen, Type IV, but not fibril-forming collagens

- and embryonic death in collagen prolyl 4-hydroxylase I null mice. *J. Biol. Chem.* 2007; 282:2512–2519. [PubMed: 17135260]
14. Myllyharju J. Prolyl 4-hydroxylases, key enzymes in the synthesis of collagens and regulation of the response to hypoxia, and their roles as treatment targets. *Ann. Med.* 2008; 40:402–417. [PubMed: 19160570]
 15. Hanauske-Abel HM, Günzler V. A stereochemical concept for the catalytic mechanism of prolylhydroxylase: Applicability to classification and design of inhibitors. *J. Theor. Biol.* 1982; 94:421–455. [PubMed: 6281585]
 16. Hausinger RP. Fe(II)/ α -ketoglutarate-dependent hydroxylases and related enzymes. *Crit. Rev. Biochem. Mol.* 2004; 39:21–68.
 17. Costas M, Mehn MP, Jensen MP, Que LJ. Dioxygen activation at mononuclear nonheme iron active sites: Enzymes, models, and intermediates. *Chem. Rev.* 2004; 104:939–986. [PubMed: 14871146]
 18. Groves JT, McClusky GA. Aliphatic hydroxylation via oxygen rebound. Oxygen transfer catalyzed by iron. *J. Am. Chem. Soc.* 1976; 98:859–861.
 19. Abraham RJ, McLauchlan KA. The proton resonance spectra and conformations of the prolines. Part I. *Mol. Phys.* 1962; 5:195–203.
 20. Hieta R, Kukkola L, Permi P, Pirilä P, Kivirikko KI, Kilpeläinen I, Myllyharju J. The peptide-substrate binding domain of human collagen prolyl 4-hydroxylases. Backbone assignments, secondary structure, and binding of proline-rich peptides. *J. Biol. Chem.* 2003; 278:34966–34974. [PubMed: 12824157]
 21. Pekkala M, Hieta R, Bergmann U, Kivirikko KI, Wierenga RK, Myllyharju J. The peptide-substrate-binding domain of collagen prolyl 4-hydroxylase is a tetratricopeptide repeat domain with functional aromatic residues. *J. Biol. Chem.* 2004; 279:52255–52261. [PubMed: 15456751]
 22. Anantharajan J, Koski MK, Kursula P, Hieta R, Bergmann U, Myllyharju J, Wierenga RK. The structural motifs for substrate binding and dimerization of the α subunit of collagen prolyl 4-hydroxylase. *Structure*. 2013; 21:2107–2118. [PubMed: 24207127]
 23. Hanauske-Abel HM. Prolyl 4-hydroxylase, a target enzyme for drug development. Design of suppressive agents and the in vitro effect of inhibitors and proinhibitors. *J. Hepatol.* 1991; 13(Suppl. 3):S8–S16.
 24. Friedman SL, Sheppard D, Duffield JS, Violette S. Therapy for fibrotic diseases: Nearing the starting line. *Sci. Transl. Med.* 2013; 5:1–17.
 25. Rose NR, McDonough MA, King ONF, Kawamura A, Schofield CJ. Inhibition of 2-oxoglutarate dependent oxygenases. *Chem. Soc. Rev.* 2011; 40:4364–4397. [PubMed: 21390379]
 26. Vasta JD, Higgin JJ, Kersteen EA, Raines RT. Bioavailable affinity label for collagen prolyl 4-hydroxylase. *Bioorg. Med. Chem.* 2013; 21:3597–3601. [PubMed: 23702396]
 27. Vasta JD, Raines RT. Selective inhibition of prolyl 4-hydroxylases by bipyridinedicarboxylates. *Bioorg. Med. Chem.* 2015; 23:3081–3090. [PubMed: 26022078]
 28. Vasta JD, Andersen KA, Deck KM, Nizzi CP, Eisenstein RS, Raines RT. Selective inhibition of collagen prolyl 4-hydroxylase in human cells. *ACS Chem. Biol.* 2016; 11:193–199. [PubMed: 26535807]
 29. Gorres KL, Pua KH, Raines RT. Stringency of the 2-His-1-Asp active-site motif in prolyl 4-hydroxylase. *PLoS One*. 2009; 4:e7635. [PubMed: 19890397]
 30. Tandon M, Wu M, Begley TP. Substrate specificity of human prolyl-4-hydroxylase. *Bioorg. Med. Chem. Lett.* 1998; 8:1139–1144. [PubMed: 9871723]
 31. Wu M, Moon H-S, Begley TP. Mechanism-based inactivation of the human prolyl-4-hydroxylase by 5-oxaproline-containing peptides: Evidence for a prolyl radical intermediate. *J. Am. Chem. Soc.* 1999; 121:587–588.
 32. Gorres KL, Edupuganti R, Krow GR, Raines RT. Conformational preferences of substrates for human prolyl 4-hydroxylase. *Biochemistry*. 2008; 47:9447–9455. [PubMed: 18702512]
 33. Gorres KL, Raines RT. Direct and continuous assay for prolyl 4-hydroxylase. *Anal. Biochem.* 2009; 386:181–185. [PubMed: 19111518]
 34. Fischer G. Chemical aspects of peptide bond isomerisation. *Chem. Soc. Rev.* 2000; 29:119–127.

35. Rapaka RS, Renugopalakrishnan V, Urry DW, Bhatnagar RS. Hydroxylation of proline in polytripeptide models of collagen: Stereochemistry of polytripeptide–prolyl hydroxylase interaction. *Biochemistry*. 1978; 17:2892–2989. [PubMed: 210786]
36. Brahmachari SK, Ananthanarayanan VS. β -Turns in nascent procollagen are sites of posttranslational enzymatic hydroxylation of proline. *Proc. Natl. Acad. Sci. U.S.A.* 1979; 76:5119–5123. [PubMed: 228279]
37. Atreya PL, Ananthanarayanan VS. Interaction of prolyl 4-hydroxylase with synthetic peptide substrates. *J. Biol. Chem.* 1991; 266:2852–2858. [PubMed: 1847136]
38. Chou PY, Fasman GD. β -Turns in proteins. *J. Mol. Biol.* 1977; 115:135–175. [PubMed: 592361]
39. Choudhary A, Raines RT. An evaluation of peptide-bond isosteres. *ChemBioChem*. 2011; 12:1801–1807. [PubMed: 21751326]
40. Keskiäho K, Hieta R, Sormunen R, Myllyharju J. *Chlamydomonas reinhardtii* has multiple prolyl 4-hydroxylases, one of which is essential for proper cell wall assembly. *Plant Cell*. 2007; 19:256–269. [PubMed: 17220203]
41. Kersteen EA, Higgin JJ, Raines RT. Production of human prolyl 4-hydroxylase in *Escherichia coli*. *Protein Expr. Purif.* 2004; 38:279–291. [PubMed: 15555944]
42. Vasta JD, Raines RT. Human collagen prolyl 4-hydroxylase is activated by ligands for its iron center. *Biochemistry*. 2016; 55:3224–3233. [PubMed: 27183028]
43. Wang XJ, Hart SA, Xu B, Mason MD, Goodell JR, Etzkorn FA. Serine–*cis*-proline and serine–*trans*-proline isosteres: Stereoselective synthesis of (*Z*)- and (*E*)-alkene mimics by Still–Wittig and Ireland–Claisen rearrangements. *J. Org. Chem.* 2003; 68:2343–2349. [PubMed: 12636401]
44. Bandur NG, Harms K, Koert U. First stereoselective synthesis of a Pro–Pro *E*-alkene dipeptide isostere. *Synlett*. 2005:773–776.
45. Bandur NG, Harms K, Koert U. Synthesis of two dipeptide isosteres containing di- and trisubstituted *E*-configured double bonds. *Synthesis*. 2007:2720–2730.
46. Dai N, Wang XJ, Etzkorn FA. The effect of a *trans*-locked Gly–Pro alkene isostere on collagen triple helix stability. *J. Am. Chem. Soc.* 2008; 130:5396–5397. [PubMed: 18366169]
47. Dai N, Etzkorn FA. *Cis–trans* proline isomerization effects on collagen triple-helix stability are limited. *J. Am. Chem. Soc.* 2009; 131:13728–13732. [PubMed: 19725497]
48. Ireland RE, Mueller RH. The Claisen rearrangement of allyl esters. *J. Am. Chem. Soc.* 1972; 94:5897–5898.
49. Hart SA, Sabat M, Etzkorn FA. Enantio- and regioselective synthesis of a (*Z*)-alkene *cis*-proline mimic. *J. Org. Chem.* 1998; 63:7580–7581.
50. Still WC, Mitra A. A highly stereoselective synthesis of *Z*-trisubstituted olefins via [2,3]-sigmatropic rearrangement. Preference for a pseudoaxially substituted transition state. *J. Am. Chem. Soc.* 1978; 100:1927–1928.
51. Myllylä R, Tuderman L, Kivirikko KI. Mechanism of the prolyl hydroxylase reaction. 2. Kinetic analysis of the reaction sequence. *Eur. J. Biochem.* 1977; 80:349–357. [PubMed: 200425]
52. Koski MK, Hieta R, Böllner C, Kivirikko KI, Myllyharju J, Wierenga RK. The active site of an algal prolyl 4-hydroxylase has large structural plasticity. *J. Biol. Chem.* 2007; 282:37112–37123. [PubMed: 17940281]
53. Koski MK, Hieta R, Hirsilä M, Rönkä A, Myllyharju J, Wierenga RK. The crystal structure of an algal prolyl 4-hydroxylase complexed with a proline-rich peptide reveals a novel buried tripeptide binding motif. *J. Biol. Chem.* 2009; 284:25290–25301. [PubMed: 19553701]
54. Walter C, Frieden E. The prevalence and significance of the product inhibition of enzymes. *Adv. Enzymol. Relat. Areas Mol. Biol.* 1963; 25:167–274.
55. Frieden E, Walter C. Prevalence and significance of the product inhibition of enzymes. *Nature*. 1963; 198:834–837. [PubMed: 13959750]
56. Cook, PF.; Cleland, WW. *Enzyme Kinetics and Mechanism*. New York: Garland Science; 2007. p. 128–150.
57. Eberhardt ES, Panasik N Jr, Raines RT. Inductive effects on the energetics of prolyl peptide bond isomerization: Implications for collagen folding and stability. *J. Am. Chem. Soc.* 1996; 118:12261–12266. [PubMed: 21451735]

58. Bretscher LE, Jenkins CL, Taylor KM, DeRider ML, Raines RT. Conformational stability of collagen relies on a stereoelectronic effect. *J. Am. Chem. Soc.* 2001; 123:777–778. [PubMed: 11456609]
59. Jenkins CL, Vasbinder MM, Miller SJ, Raines RT. Peptide bond isosteres: Ester or (*E*)-alkene in the backbone of the collagen triple helix. *Org. Lett.* 2005; 7:2619–2622. [PubMed: 15957905]
60. Horng J-C, Raines RT. Stereoelectronic effects on polyproline conformation. *Protein Sci.* 2006; 15:74–83. [PubMed: 16373476]
61. Jakobsche CE, Choudhary A, Miller SJ, Raines RT. $n \rightarrow \pi^*$ Interaction and $n(\pi)$ Pauli repulsion are antagonistic for protein stability. *J. Am. Chem. Soc.* 2010; 132:6651–6653. [PubMed: 20420451]

Figure 1.

(A) Reaction catalyzed by collagen prolyl 4-hydroxylase (CP4H). (B) Putative enzymic ligands for CP4H.^{15–17} (C) Proline analogs that are substrates for CP4H,^{30–33} despite substitutions at C^β, C^γ (*i.e.*, C4), or C^δ.

Figure 2.

Peptide substrates for CP4H and their alkene isosteres. Tetrapeptide R-Gly-Pro-Pro-Gly-OEt (**1** and **2**) can adopt a *trans* or *cis* conformation in solution. The corresponding alkene isosteres are locked as a *trans* (**3** and **4**) or *cis* (**5** and **6**) isomer.

Figure 3.

Inhibition of human CP4H1 by alkene isosteres **3–6**. (A and B) Assays were performed at pH 7.8 with dansylGPPGOEt (0.50 mM) as the substrate, α -ketoglutarate (1.00 mM), and a dansyl isostere (100 μM in panel A). (C) Assays were performed at pH 7.8 in the presence of a Cbz isostere (1.00 mM in panel C) with CbzGPPGOEt (1.00 mM) as substrate and α -ketoglutarate (1.00 mM) as a co-substrate. In all panels, values are the mean ($\pm$ SD) of three independent experiments and represent the ratio of enzymatic activity in the presence and absence of isostere.

Figure 4. Substrate inhibition of human CP4H1 by dansylGPPGOEt (**1**). (A) Velocity plot. Assays were performed at pH 7.8 with dansylGPPGOEt (58–1860 μM) as substrate and α -ketoglutarate (1.00 mM) as co-substrate. (B) Lineweaver–Burke plot of the data in panel A.

Figure 5.

Lineweaver–Burke analysis of inhibition of human CP4H1 by *cis* isostere **5**. (A) A Lineweaver–Burke plot for **5** is indicative of noncompetitive inhibition with respect to α -ketoglutarate, as the intersecting pattern that does not converge on the ordinate and the slope (B) and intercept (C) replots are linear. Assays were performed at pH 7.8 with dansylGPPGOEt (500 μM) as substrate and α -ketoglutarate (13–100 μM) as co-substrate in the presence of *cis* isostere **5** (0, 50, 100, or 150 μM). Values are the mean ($\pm$ SE) of three independent experiments.

Figure 6.

Substrate inhibition of CrP4H-1 by dansylGPPGOEt (**1**). (A) Velocity plot. Assays were performed at pH 7.8 with dansylGPPGOEt (212–2120 μM) as substrate and α -ketoglutarate (1.00 mM) as co-substrate. (B) Lineweaver–Burke plot of the data in panel A.

Figure 7.

Inhibition of *C. reinhardtii* CrP4H-1 by alkene isosteres **3** and **5**. Assays were performed at pH 7.8 with dansylGPPGOEt (0.50 mM) as the substrate, α -ketoglutarate (1.00 mM), and an alkene isostere (100 μ M). Values are the mean ($\pm$ SD) of three independent experiments and represent the ratio of enzymatic activity in the presence and absence of isostere.

Scheme 1. Synthetic route to *GPtransPGOEt trans* isosteres **3** and **4**

Scheme 2.
Synthetic route to GP_{cis}PGOEt *cis* isosteres **5** and **6**